ALEXION PHARMACEUTICALS, INC.
ALEXION PHARMACEUTICALS, INC. (ALXN): 26 pipeline candidates · ~21 mo cash runway · 66 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
21.0 months
D/E 0.50
Lead: Phase 3
26 candidates
N/A
N/A
A transparent, data-derived signal for ALEXION PHARMACEUTICALS, INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$3.5B
Quarterly Burn
$632.0M
Runway
21.0 mo
Revenue
$1.6B
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (26 candidates)
| Drug | Phase |
|---|---|
| aby-039 | Phase 1 |
| ach-5228 | Phase 2 |
| acoramidis | Phase 1 |
| ag10 | Preclinical |
| alxn1720 | Phase 3 |
| alxn1810 | Phase 3 |
| alxn1820 | Phase 3 |
| alxn1830 | Phase 3 |
| alxn1840 | Phase 3 |
| alxn1850 | Phase 3 |
Showing 10 of 26 candidates. Sign up for full pipeline.
Frequently asked questions
How many drug candidates are in ALEXION PHARMACEUTICALS, INC.'s pipeline?
ALEXION PHARMACEUTICALS, INC. (ALXN) has 26 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is ALEXION PHARMACEUTICALS, INC.'s lead drug candidate?
ALEXION PHARMACEUTICALS, INC.'s most advanced tracked candidate is aby-039 (Phase 1) for FcRn.
What is ALEXION PHARMACEUTICALS, INC.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, ALEXION PHARMACEUTICALS, INC. has approximately 21.0 months of cash runway.
Get the full picture on ALEXION PHARMACEUTICALS, INC.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.